Inhibition of aerobic glycolysis enhances the anti‐tumor efficacy of Zoptarelin Doxorubicin in triple‐negative breast cancer cells
Authors:
- 23 April 2019
- journal article
- research article
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 45 (7) , 1334-1342
Abstract
Aim: A characteristic of cancer cells including triple‐negative breast cancers (TNBC) is an increased aerobic glycolysis for ATP production representing a selective therapeutic target. More than 70% of TNBC express gonadotropin‐releasing hormone receptors (GnRH‐R). These receptors can be used for targeted chemotherapy with cytotoxic GnRH agonists such as Zoptarelin Doxorubicin, in which doxorubicin is covalently linked to [D‐Lys6]GnRH. In this study, we have analyzed whether inhibition of aerobic glycolysis can enhance the antitumor efficacy of GnRH‐R‐targeted chemotherapy using Zoptarelin Doxorubicin.Methods: Triple‐negative breast cancers cell lines MDA‐MB‐231 and HCC1806 were treated with Zoptarelin Doxorubicin, glycolysis inhibitor 2‐deoxy‐D‐glucose (2DG) or the combination of both agents. Cell viability was measured using Alamar blue. Induction of apoptosis was quantified by measurement of loss of mitochondrial membrane potential. In vivo experiments were performed using nude mice bearing xenografted MDA‐MB‐231 tumors.Results: Treatment of TNBC cells with Zoptarelin Doxorubicin or with 2DG resulted in a significant decrease of cell viability and a significant increase of apoptosis. Treatment with Zoptarelin Doxorubicin in combination with 2DG resulted in significantly reduced viability and enhanced apoptosis compared with single‐agent treatments. Combinational index (CI) analysis revealed the co‐treatment effect as a synergistic. The antitumor effects of Zoptarelin Doxorubicin or 2DG were confirmed in nude mice. The tumor reducing effects of Zoptarelin Doxorubicin were enhanced by combination with 2DG.Conclusion: The glycolytic phenotype of TNBC can be used to improve antitumor therapies. Co‐treatment of Zoptarelin Doxorubicin with glycolysis inhibitor 2DG might be a suitable therapeutic option for GnRH receptor‐positive TNBC.Keywords
Funding Information
- Deutsche Krebshilfe (111027)
This publication has 21 references indexed in Scilit:
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Comparison of methods for evaluating drug-drug interactionFrontiers in Bioscience-Elite, 2010
- Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152Neuroendocrinology, 2009
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypesHuman Pathology, 2006
- Glycolysis inhibition for anticancer treatmentOncogene, 2006
- Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1Biology of Reproduction, 2005
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 2004
- High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell linesThe Journal of Clinical Endocrinology & Metabolism, 1993
- Over-expression of facilitative glucose transporter genes in human cancerBiochemical and Biophysical Research Communications, 1990